The EGFR inhibition by erlotinib was found to overcome lenvatinib drug resistance in hepatocellular carcinoma by blocking the activation of the EGFR–STAT3–ABCB1 signaling pathway [74]. This evidence concerns the gene ABCB1 and hepatocellular carcinoma.